A B S T R A C T To determine the effect of prostaglandin E1 (PGE1) infusion upon in vivo insulin secretion, serum insulin responses after an intravenous glucose pulse (2 g) were measured before and during an intravenous infusion of PGE1 (10 Ag/min) in 11 anesthetized dogs. Circulating insulin decreased significantly during PGE1 infusion, and insulin responses after glucose during PGE1 infusion were significantly less than control responses. Three dogs received PGE1 infusions into the thoracic aorta to preclude pulmonic and hepatic degradation of PGE1 before its arrival at the pancreatic artery; inhibition of insulin secretion was again seen. Inhibition of insulin secretion could not be related to the degree of arterial hypotension induced by intravenous PGE1, and despite alpha adrenergic blockade with intravenous phentolamine, PGEi-induced inhibition of glucose-stimulated insulin responses persisted. Significant increments in systemically circulating PGE levels during intravenous PGE1 infusions were documented by radioimmunoassay. These studies demonstrate that systemic PGE1 infusion inhibits insulin secretion and that this effect could not be shown to be dependent upon alpha adrenergic activity.
INTRODUCTION
In general, prostaglandins (PG's) ' appear to be ubiquitous and have been demonstrated to modulate a variety of tissue and hormone system effects (1 (2) . Since the adrenergic nervous system has profound regulatory effects upon insulin secretion (3, 4) In all of the studies to be described, intravenous glucose was injected as a 2-g pulse (4 ml of a 50% glucose solution) in less than 3 s. Unless otherwise indicated, all infusions other than the glucose injections were given through a catheter placed in the femoral vein opposite to the one used for sample collection. Levels of serum insulin and plasma glucose were determined by previously published methods (5) Experimental design. To determine the effect of PGE1 upon insulin secretion, glucose was injected before and again during the last hour of a 2-hour intravenous PGE, (10 Ag/min) infusion. In a separate group of studies, PGE, was infused into the thoracic aorta by means of an arterial catheter passed retrograde from the femoral artery rather than into the femoral vein to preclude pulmonic and hepatic degradation of PGE1 before its arrival at the pancreatic artery. To determine the effect of alpha adrenergic blockade upon PGE1-induced effects on insulin secretion, intravenous phentolamine (0.2 mg/min) was infused for 3 h and 45 min. Intravenous glucose was given 45 min after the beginning of the phentolamine infusion. 60 min later, a 2-h infusion of PGE1 was superimposed upon the phentolamine infusion; the glucose pulse was repeated during the final hour of the PGE1 infusion. Control studies using saline instead of PGE1 were performed for all the experiments described above.
RESULTS
The effect of PGE, upon insulin secretion. Compared to basal levels of circulating insulin (31±15 /LU/ ml, mean-'-SD, n = 11), there were immediate and significant increases in insulin (mean increment, P < 0.01 at 2, 3, 4, 5, 7, and 10 min) after initial glucose injection; insulin returned to basal levels by 60 min (Fig.  1 ). After 60 min of PGE1 infusion, insulin levels fell significantly (-10±9 AU/ml, mean decrease, P < 0.01 at 60 min, Table I ) compared to the levels observed 60 min after the first glucose injection. After the second glucose injection, the increments in insulin levels were significantly less than those observed after the first glucose injection (P < 0.02 at 2 min and P < 0.01 at 3, 4, 5, and 7 min). In contrast to the PGE1 experiments, the circulating insulin levels in the control experiments at the end of the 1st h of the saline infusion (31±15 ,AU/ml) were not significantly lower than preinfusion values (33±+12 AU/ml; Fig. 2 ). The increments in insulin levels after the second glucose injection during saline infusion were significantly less than those after the first glucose injection (mean increments, P < 0.05 and < 0.01 at 5 and 10 min, respectively); however, the second glucose-induced insulin responses in the animals receiving PGE1 were significantly less than those seen in the animals receiving (2 g) given in less than 3 s upon serum insulin and plasma glucose before and during an intrathoracic aorta PGE1 infusion (10 ,ug/ min) in anesthetized dogs; mean+±SEM. saline (P < 0.01 at 2, 3, and 4 min; P < 0.02 at 5 min, Table I ). One animal treated with PGE1 infusion was deleted from the PGE1 group at the end of the study on the basis that the insulin response to the second glucose pulse was 13.77 SD's removed from the mean data of the other 11 animals. Since the probability that this response would fall within the distribution of the PGE1 group's data was P < 0.0001, this animal's exclusion as an outlier was valid (7) . There were no significant changes in circulating glucose levels during the 1st h of PGE1 or saline infusion. seen during the five control experiments with saline in which pressures were recorded. In the separate group of animals receiving PGE1 infusion into the thoracic aorta, rather than into the femoral vein (Fig. 3) , there was no increase in mean insulin levels after the second glucose pulse. Although circulating glucose levels were significantly increased over basal after the first 60 min of intra-aortic PGE1 infusion (basal = 125±4; mean increase at 60 min= + 51+22; mg/100 cc), there was no increase in mean insulin level at this time. Mean arterial blood pressure fell -51±15 mmHg during intra-aortic PGE1 infusion. Five experiments designed to determine the concentration of postpulmonic plasma immunoreactive PGE levels after 30 min of femoral vein PGE1 infusion revealed thoracic aortic plasma levels of 530+298, compared to basal levels of 88±29 (pg/cc, mean-+-SD, Table II) . The femoral vein level of PGE was determined in one animal receiving PGE1 infusion into the thoracic aorta and found to be > 2500 pg/ml.
The effect of phentolamine-induced alpha adrenergic blockade upon PGE1 effects on insulin secretion. After 45 min of phentolamine infusion in a group of five dogs (Fig. 4) , there was an increase in both mean circulating glucose (P < 0.01) and mean insulin (P = NS) over basal levels (basal: glucose = 122+8 mg/100 ml, insulin = 19+9 /AU/ml; mean increases during phentolamine: glucose + 11±4 mg/100 ml, insulin = + 19±+17 AU/ ml). After the first intravenous glucose pulse, there was an immediate increase in mean circulating insulin levels which returned to control levels by 60 min.
During the 1st h of the superimposed PGE1 infusion, there was a decrease in circulating insulin levels (-18 ±16 AU/ml, mean decrease at 60 min). After the second intravenous glucose pulse, the increments in insulin levels were significantly less (P < 0.05 for 3, 5, 7, and 10 min) than those observed after the first glucose pulse. During the control studies (Fig. 5) there was a decrease in mean circulating insulin levels -9±+14, (mean decrease +SD; n = 5) during infusion of saline rather than PGE1; although the mean decrease observed during PGE1 infusion was greater, this difference was not statistically significant. However, in contrast to the studies with PGE1 infusion, during the control studies there was no decrease in the insulin response after the second glucose pulse. The decreases in mean arterial blood pressure in the PGE1 and the saline groups were not significantly different (PGE1 = -26+14, saline =-13±15; mean-+-SD; mean decrease). DISCUSSION These studies demonstrate that intravenous PGE1 infusion in dogs partially inhibits insulin secretion, since, during PGE1 infusion, there was both a decrease in circulating insulin levels and a decrease in the height of insulin responses after intravenous glucose challenge. When saline was infused instead of PGE1, there was no decrease in circulating insulin level, and although there was an attenuation of the insulin response after the second glucose challenge, these responses were significantly greater than the corresponding responses during PGE1 infusion.
The importance of demonstrating the sixfold rise in aortic plasma immunoreactive PGE during femoral vein PGE, infusion lies in the fact that the lung immediately metabolizes an estimated 90% of PGE1 reaching the pulmonary circulation (8) . The aortic plasma PGE levels reported herein suggest that an adequate amount of PGE escaped pulmonic degradation to have systemic effects. Moreover, the systemic hypotension observed during the infusions is compatible with physiologically significant elevations of postpulmonic PGE levels. The fact that supraphysiologic postpulmonic levels of PGE supplied by intra-aortic PGE1 infusion also inhibited insulin secretion further supports the contention that increases in systemically circulating PGE result in decreased insulin secretion.
Catecholamines are well-known profound inhibitors of insulin secretion in both the basal and stimulated state, an effect mediated by the stimulation of the alpha adrenergic receptor (3, 4 blockade with phentolamine did not reverse PGEi-induced inhibition of insulin secretion does not support the notion that this PGE1 effect was secondary to reflex endogenous catecholamine secretion-a theoretical possibility in view of PGE,-induced hypotension. However, since clinical hypotension has been associated with inhibition of insulin secretion (9, 10) , it is possible that the inhibitory effect of PGE1 upon insulin secretion may be secondary to the modest hypotensive effects encountered in these studies, even though there was no correlation between the magnitude of these two effects. It is of interest that there were diminished responses to the second glucose pulse in the group receiving saline alone but not in the group receiving saline and phentolamine. This suggests that nonspecific stress experienced by the animals during intubation, surgery, and blood loss may have activated alpha adrenergic receptors, perhaps through catecholamine secretion, which would have tended to diminish insulin responses. The fact that phentolamine infusion appeared to prevent a decrease in glucose-stimulated insulin responses after the second glucose pulse in the group receiving saline rather than PGEL further suggests that PGE1 effects were not dependent upon alpha adrenergic activity.
PGE1 has been reported to stimulate, rather than to inhibit, insulin secretion in isolated pancreatic islets (11) . Increased insulin levels have also been reported in mice after interperitoneal PGE1 (12) , but it is not clear whether this increase in insulin secretion was caused by PGEi alone or by the associated hyperglycemia noted during these studies. During intravenous PGE1 infusion in sheep (13) and during intravenous PGE, infusions in pregnant humans (14) , no significant effect upon basal insulin or glucose level was noted: however, in the latter study, the rate of infusion was not constant, and in neither study was intravenous glucose stimulation attempted. Systemic hypotension and decreased pancreaticoduodenal vein blood flow, -but no change in insulin output from the pancreaticoduodenal vein in dogs during PGE1 infusion, has been reported; however, in these studies, a marked increase in insulin output occurred after discontinuation of PGE1 (15) .
Since stress plays such a key role in the regulation of insulin secretion, it is difficult to compare directly these results from dogs underging major surgical stress to the dogs described in the present study who were stressed much less. However, it can be speculated that the postPGEi infusion increase in insulin output observed may have reflected prior suppression of insulin secretion during PGEi infusion. Inhibition of glucose-stimulated insulin secretion during intravenous PGAL infusion in fasting anesthetized dogs has been demonstrated, but neither arterial blood pressure values nor attempts to reverse the PGA1 effect with alpha adrenergic blockade were reported in this study (16) .
In conclusion, these studies have demonstrated that intravenous PGE, infusion inhibits insulin secretion in anesthetized dogs. This effect, however, may or may not be due directly to the infused PGE1. It is entirely possible that the PGE1 infusion caused endogenous formation or secretion of some unidentified substance which was responsible for the observed inhibition of insulin secretion. However, if this effect was not due to PGE1 directly, these data do not suggest it was related to alpha adrenergic activity.
